ClinicalTrials.gg
Not yet recruitingNCT07951463Updated Nov 20, 2026

A Study of Glumetinib in Combination With Osimertinib as 1st Line Treatment in Patients With Non-Small Cell Lung Cancer

A Phase 3 interventional study of Glumetinib Tablets and Placebo in Non-small Cell Lung Cancer, sponsored by Shanghai JMT-Bio Inc.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Shanghai JMT-Bio Inc. (part of CSPC Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 18 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited — 12 open to participants now, 13 under way, 8 of them phase 3. Carcinoma, Non-Small-Cell Lung · CSPC Pharmaceutical Group Limited.

Planned enrollment
9th of 17
375 · median 375
Started
2026
with 4 others
Phase 3
8 of 18
7 open now
Primary completion
2029-04
later than 11 of 12 live
Registered
18th of 18
by date

Among the 18 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited, this one is the 9th largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2026, is one of 8 in phase 3, reaches primary completion later than 11 of the 12 other live ones, and was the 18th registered.

Carcinoma, Non-Small-Cell Lung

7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

12 of the 18 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 226 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of Glumetinib plus Osimertinib in patients with non-small cell lung cancer with classic EGFR mutations and MET overexpression or amplification.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and willingness to voluntarily provide written .
  2. Age 18 to 75 years, males or females.
  3. Patientsconfirmed unresectable locally advanced or NSCLC patients;.
  4. Ability to provide qualified tumor samples..
  5. Patients must harbor the 1 of the 2 common EGFR mutations clearly associated with EGFR-TKI sensitivity (i.e., 19Del and L858R) as well as MET overexpression and/or amplification. MET overexpression and amplification must be confirmed by the central laboratory.
  6. No prior systemic anticancer therapy (including chemotherapy, radiotherapy, biological therapy, immunotherapy, or any drugs) for locally advanced or metastatic NSCLC, and the participant is not amenable to curative surgery or radiotherapy. For patients with recurrent disease following prior surgery, if prior chemo/radiotherapy, neoadjuvant chemo/radiotherapy, or definitive chemoradiotherapy for advanced disease was received, disease progression should have occurred ≥ 6 months after the completion of the last treatment.
  7. Presence of at least one at baseline according to v1.1. The target lesion must not have received prior irradiation, or if previously irradiated, must show documented evidence of disease progression after radiotherapy. cannot be selected as target lesions.
  8. (ECOG) performance status (PS) of 0 or 1.
  9. ≥ 3 months.
  10. Adequate bone marrow reserve or organ function..
  11. Women of must use highly effective . Women of childbearing potential must have a negative blood pregnancy test within 7 days before the first dose. Any male or female participant of childbearing potential must agree to use highly effective contraception throughout the study period and for 6 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with any EGFR inhibitor or MET inhibitor.
  2. Concomitant driver alterations such as ALK, ROS1, RAS, BRAF, RET, and for which approved targeted therapies are clinically available, if the Investigator judges that the patients cannot benefit from this trial due to the concomitant alteration; or other alterations (e.g., those with substantial clinical evidence supporting a better intervention for the mutation) that, in the Investigator's judgment, preclude benefit from this trial..
  3. Prior antineoplastic therapy within 2 weeks prior to the first dose of study drug, including hormonal therapy, biologic therapy, immunotherapy (including but not limited to /PD-L1 antibodies, anti-CTLA-4 antibodies, cellular immunotherapy, etc.), local infusion of antineoplastic agents, or Chinese herbal medicines and/or proprietary Chinese patent medicines with approved/intended indications for the treatment of lung cancer.
  4. Prior local radiotherapy (including radionuclide therapy such as strontium-89) within 2 weeks before the first dose of study drug; or, within 4 weeks before randomization, received bone marrow irradiation exceeding 30% or extensive-field radiotherapy..
  5. Clinically uncontrolled (requiring paracentesis or drainage) malignant pleural effusion, ascites, or pericardial effusion within 2 weeks prior to the first dose of study drug.
  6. Major surgical procedure or significant traumatic injury within 4 weeks prior to the first dose of study drug, or anticipated need for major surgery during the study period. Minor clinical procedures such as vascular access placement and core/needle are permitted.
  7. Presence of ; presence of spinal cord compression; or symptomatic and unstable , unless the participant has completed definitive treatment, has achieved neurological stability for at least 2 weeks prior to randomization, and requires no or anticonvulsants. Asymptomatic patients with brain metastases (e.g., without neurological deficits, seizures, or other typical signs/symptoms of central nervous system [CNS] ) may be enrolled if the investigator assesses that there is no indication for immediate definitive intervention.
  8. Use of strong inducers within 2 weeks prior to the first dose of study drug, or inability to discontinue strong CYP3A4 inducers during the study period.
  9. History of diseases, immunodeficiency disorders (including positive serology), other acquired or congenital immunodeficiency diseases, or history of solid organ or bone marrow transplantation.
  10. Active infection (e.g., the participant is receiving anti-infective therapy).
  11. Severe or uncontrolled cardiovascular diseases requiring medical treatment.
  12. History of to the active or inactive of osimertinib, gumarontinib/placebo, or chemotherapy agents (pemetrexed and cisplatin/carboplatin), or to drugs of similar chemical structure or class; to chemotherapy agents (pemetrexed and cisplatin/carboplatin).
  13. Failure to adequately recover from toxicities and/or complications resulting from any prior interventions prior to treatment initiation (i.e., not recovered to Grade ≤ 1, excluding fatigue or alopecia).
  14. Current diagnosis of other or a history of other active malignancies within 5 years prior to the first study treatment, with the exception of clinically cured localized neoplasms (e.g., basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder carcinoma, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, or papillary thyroid carcinoma).
  15. Definite prior history of neurological or psychiatric disorders, including epilepsy or dementia.
  16. Pregnant or lactating women.
  17. Participation in another drug clinical trial and receipt of investigational drug within 3 weeks prior to the first dose of study drug.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
375 participants (estimated)

Study arms

  • Experimental
    Arm A

    Glumetinib 300 mg orally once daily (QD) + Osimertinib 80 mg orally QD,every 3 weeks

    Drug: Glumetinib Tablets · Drug: Osimertinib Mesylate Tablets

  • Placebo comparator
    Arm B

    Placebo 300 mg orally QD + Osimertinib 80 mg orallyQD,every 3 weeks

    Drug: Placebo · Drug: Osimertinib Mesylate Tablets

  • Active comparator
    Arm C

    Osimertinib 80 mg QD and platinum-based chemotherapy Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

    Drug: Osimertinib Mesylate Tablets · Drug: Pemetrexed/Carboplatin · Drug: Pemetrexed/Cisplatin

Interventions

  • DrugGlumetinib Tablets

    Glumetinib 300 mg QD orally under fasting conditions

  • DrugPlacebo

    Placebo 300 mg QD orally under fasting conditions

  • DrugOsimertinib Mesylate Tablets

    Administered orally at a dose of 80 mg QD orally

  • DrugPemetrexed/Carboplatin

    Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

  • DrugPemetrexed/Cisplatin

    Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

06

What researchers measure

Primary outcomes

  1. FS as assessed by IRC

    Progression-free survival (PFS) using IRC as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)

    Time frame: Up to approximately 42 months after the first patient is enrolled

Secondary outcomes

  1. ORR as assessed by IRC

    Objective response rate (ORR) as assessed by IRC

    Time frame: Up to approximately 42 months after the first patient is enrolled

  2. DCR as assessed by IRC

    Disease control rate (DCR) as assessed by IRC

    Time frame: Up to approximately 42 months after the first patient is enrolled

  3. DOR as assessed by IRC

    Duration of Response (DOR) as assessed by IRC

    Time frame: Up to approximately 42 months after the first patient is enrolled

  4. TTR as assessed by IRC

    Time to Response (TTR) as assessed by IRC

    Time frame: Up to approximately 42 months after the first patient is enrolled

  5. PFS as assessed by Investigator

    PFS as assessed by Investigator

    Time frame: Up to approximately 42 months after the first patient is enrolled

  6. ORR as assessed by Investigator

    ORR as assessed by Investigator

    Time frame: Up to approximately 42 months after the first patient is enrolled

  7. DCR as assessed by Investigator

    DCR as assessed by Investigator

    Time frame: Up to approximately 42 months after the first patient is enrolled

  8. DOR as assessed by Investigator

    DOR as assessed by Investigator

    Time frame: Up to approximately 42 months after the first patient is enrolled

  9. TTR as assessed by Investigator

    TTR as assessed by Investigator

    Time frame: Up to approximately 42 months after the first patient is enrolled

  10. OS

    Overall Survival (OS)

    Time frame: Up to approximately 42 months after the first patient is enrolled

  11. Safety

    Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs), the other safety variables including physical examination, vital signs and laboratory examinations.

    Time frame: Up to approximately 42 months after the first patient is enrolled

  12. PK parameters

    Plasma concentration of Glumetinib

    Time frame: Up to approximately 42 months after the first patient is enrolled

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2029, 27 months later.

Of 314 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 27 months is below that.

Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Dec 31, 2026
Primary completionEst.
Apr 30, 2029
CompletionEst.
Aug 31, 2030
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07951463
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Dec 31, 2026 (estimated)
Primary completion
Apr 30, 2029 (estimated)
Completion
Aug 31, 2030 (estimated)
Last update
Nov 20, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
031169085587

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion